A trial of sulfamethoxazole (SMX) -trimethoprim (TMP) combination product was conducted in 14 patients, mainly consisting of cases with respiratory tract infections. The drug was given 4 tablets daily for 4-23 days. Bacteriological cure followed in all of the 6 patients, in whom bacteriological studies were possible before and after the treatment. Of 12 clinically evaluable cases, 8 patients were classified as good responders and 4 as fair.
One patient complained of nausea and another developed probable sulfa-sensitivity manifested by fever, skin eruption and emesis. No hematological or hepato-renal disturbance was observed.
